{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:38:55Z","timestamp":1790613535635,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01223-y","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:11:03Z","timestamp":1722330663000},"page":"2223-2234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-2333","authenticated-orcid":false,"given":"Kristen","family":"Bibeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6907-0846","authenticated-orcid":false,"given":"Kathleen","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Skaltsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3137-5601","authenticated-orcid":false,"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"1","key":"1223_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77(1):1\u201313.","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"1223_CR2","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1223_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kruger","year":"2012","unstructured":"Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51(10):1206\u201312.","journal-title":"Int J Dermatol"},{"issue":"12","key":"1223_CR4","first-page":"797","volume":"96","author":"S Plensdorf","year":"2017","unstructured":"Plensdorf S, Livieratos M, Dada N. Pigmentation disorders: diagnosis and management. Am Fam Phys. 2017;96(12):797\u2013804.","journal-title":"Am Fam Phys"},{"issue":"4","key":"1223_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","volume":"178","author":"O Osinubi","year":"2018","unstructured":"Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863\u201378.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1223_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374.","journal-title":"Am J Clin Dermatol"},{"key":"1223_CR7","unstructured":"Incyte Biosciences UK Ltd. Opzelura\u2122 (ruxolitinib cream). Summary of product characteristics. 2023. https:\/\/www.medicines.org.uk\/emc\/product\/14903\/smpc#about-medicine. Accessed 22 Feb 2024."},{"key":"1223_CR8","unstructured":"Incyte Biosciences Distribution B.V. Opzelura\u2122 (ruxolitinib cream). Summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opzelura-epar-productinformation_en.pdf. Accessed 22 Feb 2024."},{"key":"1223_CR9","unstructured":"Incyte Corporation. Opzelura\u2122 (ruxolitinib cream). Full prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215309s001lbl.pdf. Accessed 22 Feb 2024."},{"issue":"10244","key":"1223_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"key":"1223_CR11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445\u201355.","journal-title":"N Engl J Med"},{"issue":"6","key":"1223_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677\u201383.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1223_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.13432","volume":"172","author":"L Komen","year":"2015","unstructured":"Komen L, da Graca V, Wolkerstorfer A, de Rie MA, Terwee CB, van der Veen JP. Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. Br J Dermatol. 2015;172(2):437\u201343.","journal-title":"Br J Dermatol"},{"key":"1223_CR14","unstructured":"US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009.  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed 1 Mar 2024."},{"issue":"2","key":"1223_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363.","journal-title":"J Chiropr Med"},{"issue":"3","key":"1223_CR16","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69\u201371.","journal-title":"Malawi Med J"},{"issue":"3","key":"1223_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan GM, Feinn R. Using effect size-or why the P value is not enough. J Grad Med Educ. 2012;4(3):279\u201382.","journal-title":"J Grad Med Educ"},{"issue":"1","key":"1223_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","volume":"27","author":"CD Coon","year":"2018","unstructured":"Coon CD, Cook KF. Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res. 2018;27(1):33\u201340.","journal-title":"Qual Life Res"},{"issue":"8","key":"1223_CR19","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00403-023-02608-3","volume":"315","author":"MS Ceresnie","year":"2023","unstructured":"Ceresnie MS, Warbasse E, Gonzalez S, Pourang A, Hamzavi IH. Implementation of the Vitiligo Area Scoring Index in clinical studies of patients with vitiligo: a scoping review. Arch Dermatol Res. 2023;315(8):2233\u201359.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1223_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2021.06.880","volume":"86","author":"JM Bae","year":"2022","unstructured":"Bae JM, Zubair R, Ju HJ, et al. Development and validation of the fingertip unit for assessing Facial Vitiligo Area Scoring Index. J Am Acad Dermatol. 2022;86(2):387\u201393.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01223-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01223-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01223-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:30:35Z","timestamp":1724077835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01223-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01223-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kristen Bibeau (currently Moderna), Kathleen Butler (currently Astria Therapeutics, Inc.), and Mingyue Wang (currently Boehringer Ingelheim) are former employees of Incyte Corporation and are shareholders of Incyte. Konstantina Skaltsa is an employee of IQVIA contracted by Incyte Corporation to perform the psychometric analysis reported in this article. Iltefat H Hamzavi has served as an advisory board member for AbbVie; as a consultant for Boehringer Ingelheim, Galderma Laboratories LP, Incyte Corporation, Pfizer, and UCB; as a principal investigator for Avita, Bayer, Est\u00e9e Lauder, Ferndale Laboratories, Incyte Corporation, Lenicura, L\u2019Or\u00e9al, Pfizer, and Unigen; as a subinvestigator for Arcutis; as president of the HS Foundation; and as board member of the Global Vitiligo Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The trial protocols were approved by an institutional review board or ethics committee at participating centers. Trials were conducted in accordance with the Declaration of Helsinki and adhered to trial protocols, Good Clinical Practice, and applicable country-specific laws and regulations. Written informed consent or assent was provided by all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}